PrCasirivimab and imdevimab for injection
Casirivimab and imdevimab for injection are authorized under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19.
Solution for infusion, each available as 1332 mg/11.1 mL and 300 mg/2.5 mL (120mg/mL) single-use vials
Anti-SARS-CoV-2 spike protein monoclonal antibodies
(1332 mg/11.1 mL)
(300 mg /2.5 mL)
For more information, please see below to be redirected to:
For more information or to report adverse events, please contact us